Guy Adami: Alkermes a 'No-Play' at This Level By: CNBC.com News January 09, 2012 at 18:12 PM EST Alkermes expects FDA approval for its new diabetes drug this month, but that might not be enough to make the stock worth buying, trader Guy Adami said. Read More >> Related Stocks: Alkermes Plc